Crescent Biopharma, Inc. (CBIO) FinancialsCBIOCrescent Biopharma, Inc.

Evaluating the bottom line, Crescent Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4917.52%, while the net margin is -4631.38%. These profitability ratios, combined with a Return on Equity (ROE) of -113.49%, provide a clear picture of how effectively CBIO converts its operational activities into shareholder value.

In the context of the broader market, CBIO competes directly with industry leaders such as PRME and VSTM. With a market capitalization of $669.33M, it holds a leading position in the sector. When comparing efficiency, CBIO's gross margin of 100.00% stands against PRME's 100.00% and VSTM's 89.92%. Such benchmarking helps identify whether Crescent Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

Crescent Biopharma has shown significant revenue growth potential with a gross margin of 100% in the last two quarters, indicating that once sales commence, profitability could be strong. However, the company has been operating at a loss with a net income of -24,837,000 USD in Q2 2026.